Five- and 10-year overall survival by primary diagnosis and cGVHD status in patients surviving disease-free for 2 years after allogeneic HCT
| Diagnosis . | Overall . | Without cGVHD . | With cGVHD . | 10-y . | ||
|---|---|---|---|---|---|---|
| 5-y . | 10-y . | 5-y . | 10-y . | 5-y . | ||
| Entire cohort | 90.2 (0.8) | 84.6 (1.3) | 95.1 (0.9) | 91.0 (1.4) | 85.5 (1.4) | 78.1 (2.1) |
| Acute myeloid leukemia | 89.3 (1.6) | 82.8 (2.4) | 95.5 (1.5) | 92.1 (2.3) | 83.0 (2.8) | 73.2 (4.2) |
| Chronic myeloid leukemia | 90.4 (1.5) | 83.3 (2.5) | 94.4 (1.9) | 89.5 (3.5) | 88.2 (2.1) | 79.8 (3.4) |
| Acute lymphoblastic leukemia | 88.5 (2.1) | 83.9 (3.0) | 93.6 (2.1) | 86.7 (3.5) | 82.5 (3.9) | 81.5 (5.2) |
| Non-Hodgkin lymphoma | 86.7 (5.5) | 70.7 (10.6) | 92.9 (7.9) | 80.0 (14.7) | 83.3 (7.3) | 64.8 (14.5) |
| Severe aplastic anemia | 95.9 (1.5) | 93.8 (2.2) | 99.1 (0.9) | 99.1 (1.2) | 90.7 (3.7) | 85.5 (4.9) |
| Inborn errors of metabolism | 89.1 (3.6) | 86.4 (5.6) | 92.3 (3.5) | 90.5 (5.8) | 77.8 (9.8) | 72.2 (12.7) |
| Diagnosis . | Overall . | Without cGVHD . | With cGVHD . | 10-y . | ||
|---|---|---|---|---|---|---|
| 5-y . | 10-y . | 5-y . | 10-y . | 5-y . | ||
| Entire cohort | 90.2 (0.8) | 84.6 (1.3) | 95.1 (0.9) | 91.0 (1.4) | 85.5 (1.4) | 78.1 (2.1) |
| Acute myeloid leukemia | 89.3 (1.6) | 82.8 (2.4) | 95.5 (1.5) | 92.1 (2.3) | 83.0 (2.8) | 73.2 (4.2) |
| Chronic myeloid leukemia | 90.4 (1.5) | 83.3 (2.5) | 94.4 (1.9) | 89.5 (3.5) | 88.2 (2.1) | 79.8 (3.4) |
| Acute lymphoblastic leukemia | 88.5 (2.1) | 83.9 (3.0) | 93.6 (2.1) | 86.7 (3.5) | 82.5 (3.9) | 81.5 (5.2) |
| Non-Hodgkin lymphoma | 86.7 (5.5) | 70.7 (10.6) | 92.9 (7.9) | 80.0 (14.7) | 83.3 (7.3) | 64.8 (14.5) |
| Severe aplastic anemia | 95.9 (1.5) | 93.8 (2.2) | 99.1 (0.9) | 99.1 (1.2) | 90.7 (3.7) | 85.5 (4.9) |
| Inborn errors of metabolism | 89.1 (3.6) | 86.4 (5.6) | 92.3 (3.5) | 90.5 (5.8) | 77.8 (9.8) | 72.2 (12.7) |
Data are all percentages (SE).